Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

EHA 2019 | Top CLL news summer 2019

Lydia Scarfò • 15 Jun 2019
EHA 2019
Chronic Lymphocytic Leukemia Leukemia Ibrutinib Obinutuzumab Venetoclax

Lydia Scarfò, MD, Vita-Salute San Raffaele University & IRCCS San Raffaele Scientific Institute, Milan, rounds up the top CLL news presented at this years EHA meeting and tells us what she is looking forward to at ASH 2019. This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

More from Lydia Scarfò

From fixed-duration regimens to novel agents: current & future perspectives on CLL treatment
2:34
From fixed-duration regimens to novel agents: current & future perspectives on CLL treatment
Lydia Scarfò • 4 Sep 2025
MRD assessment in CLL: importance of standardizing tests & potential clinical application
3:04
MRD assessment in CLL: importance of standardizing tests & potential clinical application
Lydia Scarfò • 4 Sep 2025
Tailoring therapy for younger, fit patients with CLL: advice for community oncologists
2:17
Tailoring therapy for younger, fit patients with CLL: advice for community oncologists
Lydia Scarfò • 5 Sep 2025
The importance of integrating genetic profiling in CLL: from NGS to emerging biomarkers
1:39
The importance of integrating genetic profiling in CLL: from NGS to emerging biomarkers
Lydia Scarfò • 4 Sep 2025

Related Videos

The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
2:53
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
Lydia Scarfò • 6 Dec 2025
Bexobrutideg in CLL and approaching the sequencing of BTK degraders and inhibitors
2:20
Bexobrutideg in CLL and approaching the sequencing of BTK degraders and inhibitors
Lydia Scarfò • 6 Dec 2025
Beat AML abstracts at ASH 2025: ficlatuzumab sub-study, PRISM score, and the impact of co-mutations
3:16
Beat AML abstracts at ASH 2025: ficlatuzumab sub-study, PRISM score, and the impact of co-mutations
Lydia Scarfò • 6 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
Lydia Scarfò • 15 Dec 2025
The content of VJHemOnc is intended for healthcare professionals